Moderna shares rose nearly 20% after Science Day, driven partly by a short squeeze, while its mRNA pipeline beyond vaccines ...

Moderna Inc. Chief Executive Officer Stephane Bancel said he sees the pending launch of a planned flu vaccine as a chance to ...

Cancer was a key focus, with programs targeting solid tumors, Lynch syndrome, melanoma, and non-small cell lung cancer.

Your resource for the hottest moving stocks and news. We cover all sectors and markets giving everyday investors access to ...

A federal vaccine advisory panel today gave its stamp of approval to Moderna’s mRNA influenza vaccine (mRNA-1010) for older ...

AI and mRNA drive cancer vaccine gains as MSD, Moderna cut melanoma relapse Personalized melanoma shot from Msd and Moderna ...

A first-of-its-kind flu shot is one step closer to being available to the public after a Food and Drug Administration (FDA) advisory panel voted Thursday to recommend Moderna’s mRNA-based vaccine for ...

Moderna just received fantastic news.

Moderna’s mRNA-centric business is in conflict with the U.S. government’s shifting views on mRNA technology, and analysts say that’s a risk. The biotech announced Tuesday evening that in a rare move, ...

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up 14% to $68 and change in afternoon trading Friday, extending a ...

The biotech company said the FDA won't review its flu vaccine, in the latest hit to mRNA development As COVID-19 vaccine sales dwindle, pressure on Moderna to grow its business has increased.